Search the Newsreel

Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases

Dianthus Therapeutics has announced DNTH312, a new first-in-class, next-generation bifunctional fusion protein aimed at treating severe autoimmune diseases. This investigational drug combines claseprubart and TACI, targeting both active C1s and BAFF/APRIL pathways to provide comprehensive inhibition of B cell activity and Classical Pathway inflammation. …

Synthomer (LON:SYNT) Releases Quarterly Earnings Results

Synthomer H1 Earnings Call Highlights

Key Points Interested in Synthomer plc? Here are five stocks we like better. Synthomer delivered a stronger-than-expected first half, with revenue up 6.7%, EBITDA up 13% and margins expanding to 10.1%. Growth was driven by specialty products, cost actions and supply-chain disruption benefits. The …

Curium to acquire Lantheus in all-cash deal worth up to $8bn

CapVest Partners-backed Curium has agreed to buy rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn. The deal will take the Nasdaq-listed Lantheus private. Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per …

LightInTheBox Holding Co., Ltd. Sponsored ADR Revenue Breakdown – MUN:L4X

LightInTheBox Holding Co., Ltd. Sponsored ADR (MUN:L4X) generated €190.97 million in revenue last year. The Product Sales segment was the highest-performing, bringing in €525.53 million, an increase from €235.41 million in the prior year. Europe was the largest regional contributor, accounting for €266.97 million …

Anthem Biosciences shares gain over 2% today

Renaissance Technologies LLC Boosts Stock Holdings in Gentherm Inc $THRM

Synthomer (LON:SYNT) Earns "Buy" Rating from Peel Hunt

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Anthem Biosciences shares decline 2.19% on Tuesday

Earnings Flash (SYNT.L) Synthomer plc Posts H1 Loss GBX-3.1

Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Lantheus Holdings, Inc. (NASDAQ: LNTH) following its recently announced transaction with Curium, questioning if the deal provides a fair price for public shareholders. Lantheus shareholders are set to receive $102.50 per share in cash, plus Contingent Value Rights potentially worth …

Lantheus (LNTH) Agrees To Join Curium In Radiopharmaceuticals Deal

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Curium has entered into a definitive agreement to acquire Lantheus Holdings (NasdaqGM:LNTH) in a transaction that will combine their radiopharmaceutical businesses. The deal …

Dianthus Therapeutics grants stock options to s...

Dianthus Therapeutics has granted 87,000 stock options to six new non-executive employees. These options, with a 10-year term and an exercise price of $106.02 per share, vest over four years and were approved under Nasdaq rules to incentivize new hires. Dianthus is a clinical-stage …

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Dianthus Therapeutics, Inc. has announced the issuance of inducement grants to six newly-hired, non-executive employees on August 3, 2026. These grants, approved by the Company's independent Compensation Committee, consist of non-qualified stock options to purchase an aggregate of 87,000 shares of common stock with …

Northrop Grumman (NOC) Lands Over $3 Billion In Missile Defense Deals

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Northrop Grumman secured two multi year defense agreements exceeding $3 billion to accelerate production and delivery of critical munitions and missile defense technologies. …

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH)

Monteverde & Associates PC, a class action law firm, has announced an investigation into Lantheus Holdings, Inc. (NASDAQ: LNTH) following its proposed sale to Curium US Holdings LLC. Shareholders are set to receive $102.50 per share in cash, plus potential contingent value rights of …

Lantheus Stock Is Gaining Monday: What's Going On? - Lantheus Holdings (NASDAQ:LNTH)

Global investment firm CapVest Partners' portfolio company Curium is set to acquire Lantheus Holdings (NASDAQ:LNTH) in a deal valued at up to $8 billion. Lantheus shareholders will receive $102.50 per share in cash, plus contingent value rights potentially adding $12.00 per share, totaling up …

Curium deepens radiopharma heft with up to $8 billion deal for Lantheus

By Kamal Choudhury and Kunal Das Aug 3 (Reuters) - Radiopharmaceutical company Curium has agreed to buy peer Lantheus Holdings in a deal worth up to $8 ‌billion, as the private equity-backed firm looks to expand its footprint in ‌the fast-growing sector. Radiopharmaceuticals, which …

Lantheus Holdings to Be Acquired for Initial $6.7 Billion

Lantheus Holdings is set to be acquired by Curium, a radiopharmaceutical company backed by CapVest Partners, for an initial $6.7 billion. Curium will pay $102.50 per share in cash, representing a 2.9% premium over Friday's closing price. This acquisition follows Lantheus's comprehensive evaluation of …

Curium Announces Definitive Agreement to Merge with Lantheus

Curium and Lantheus Holdings, Inc. have announced a definitive agreement for Curium to acquire Lantheus for up to $8.0 billion. The transaction involves a cash payment of $102.50 per share at closing, plus Contingent Value Rights of up to $12.00 per share tied to …

Curium to buy Bedford-based Lantheus in deal worth up to $8B

Curium is set to acquire Lantheus, a 70-year-old radiopharmaceutical company based in Massachusetts, for up to $8 billion. The acquisition highlights a significant transaction in the radiopharmaceutical field, though the future of Lantheus' Massachusetts workforce remains uncertain. The deal was reported by the Boston …

LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per share in cash, plus potential additional contingent value rights. The firm is examining whether Lantheus and its board …

Lantheus Holdings to Merge With Curium US Holdings in Up to $8 Billion Transaction Closing in H1 2027

Lantheus Holdings is set to merge with Curium US Holdings in a transaction valued at up to $8 billion, which is expected to close in the first half of 2027. This acquisition will see Curium expanding its radiopharma capabilities by integrating Lantheus, a company …

Northrop Grumman Enters Into $3 Billion Landmark Agreements to Accelerate Missile Interceptor Production

Northrop Grumman Corporation Multi-year framework agreements with the U.S. Department of War and Lockheed Martin deliver speed, scale and certainty for the United States and allies FALLS CHURCH, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Northrop Grumman (NYSE: NOC) has signed two multi-year framework …

Sei Investments Co. Acquires 78,388 Shares of Dianthus Therapeutics, Inc. $DNTH

Sei Investments Co. significantly increased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 566.3%, acquiring an additional 78,388 shares in the first quarter, bringing its total to 92,229 shares valued at $7.74 million. Other institutional investors also adjusted their holdings, with several analysts reiterating …

Curium strikes up to $8 billion deal for radiopharma peer Lantheus

Curium has agreed to acquire radiopharmaceutical company Lantheus Holdings in a deal valued at up to $8 billion. Lantheus shareholders will receive $102.50 per share in cash, with potential additional payments of up to $12 per share based on sales targets, representing a 14.9% …

Indo Rama Synthetics Sees Significant Price Rise of 8.79%

Lantheus Holdings Inc Revenue Breakdown – SWB:0L8

Lantheus Holdings Inc (SWB:0L8) generated €1.31 billion in revenue last year, with its PYLARIFY segment being the top performer, contributing €842.15 million. The United States was the largest geographical contributor, accounting for €1.24 billion of the total revenue. These figures show a slight increase …

DV Trading LLC Acquires Shares of 26,551 Dianthus Therapeutics, Inc. $DNTH

DV Trading LLC recently acquired 26,551 shares of Dianthus Therapeutics (NASDAQ:DNTH) valued at approximately $2.23 million. Despite a recent 5.1% drop in stock price, Dianthus Therapeutics reported better-than-expected quarterly losses, and analysts maintain a "Moderate Buy" rating with a target price of $117.82. However, …

Northrop Grumman (NOC) Hebt Die Prognose An, Ist Die Aktie Weiter Unter Dem Fairen Wert?

Panthera Resources Plc Revenue Breakdown – LSE:PAT

EcoSynthetix Q2 Earnings Call Highlights

Key Points Interested in EcoSynthetix Inc.? Here are five stocks we like better. Q2 results weakened: Sales fell 9% year over year to CAD 4.5 million, while adjusted EBITDA declined to a CAD 150,000 loss from a CAD 240,000 profit, primarily due to lower …

The Bull Case For Gentherm (THRM) Could Change Following New $400 Million Buyback Plan And Q2 Results

EcoSynthetix Inc. 2026 Q2 - Results - Earnings Call Presentation (TSX:ECO:CA) 2026-08-01

Lantheus Holdings (LNTH) Pipeline Narrative Holds Firm, Does The Stock Look Fully Valued?

Lantheus Holdings (LNTH) shares recently closed at US$101, showing a strong year-to-date return of 50.14% despite a recent 9% dip. The company is considered 3% undervalued with a fair value of $104 per share, driven by an expanding radiodiagnostic pipeline including multiple new product …